Prolonged Daily Temozolomide for Low-Grade Glioma

Inclusion Criteria: * Histological confirmation of a low-grade glioma (astrocytoma, oligodendroglioma, or mixed oligoastrocytoma) * Measurable disease on MRI * Patients that have undergone recent resection for newly diagnosed or recurrent or progressive tumor are eligible if they have recovered from the effects of surgery. * Patients with recurrent disease my have had one prior chemotherapy regimen * Older than 18 years of age. * Karnofsky performance status (KPS) performance score of \> 70% * Adequate hematologic, renal and liver functions, * Life expectancy of greater than 12 weeks. * Negative pregnancy test. Exclusion Criteria: * Prior treatment with temozolomide * Patients who are not neurologically stable * Acute infection treated with intravenous antibiotics * Non-malignant systemic disease * Frequent vomiting, inability to swallow or a medical condition that could interfere with oral medication. * Previous or concurrent malignancies at other sites, with the exception of surgically cured carcinoma in-situ of the cervix, and basal or squamous cell carcinoma of the skin. * HIV positive or AIDS-related illness * Pregnant or nursing women * Patients with allergy to decarbazine.